Table of Contents
ISRN Oncology
Volume 2011, Article ID 787490, 12 pages
Review Article

Innovative Therapies against Human Glioblastoma Multiforme

Department of Basic and Applied Biology, University of l'Aquila, Via Vetoio No. 10, 67010 L'Aquila, Italy

Received 24 April 2011; Accepted 25 May 2011

Academic Editors: A. Abdollahi and N. Fujimoto

Copyright © 2011 Annamaria Cimini and Rodolfo Ippoliti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Glioblastoma multiforme is the most invasive and aggressive brain tumor in humans, and despite the latest chemical and radiative therapeutic approaches, it is still scarcely sensitive to these treatments and is generally considered an incurable disease. This paper will focus on the latest approaches to the treatment of this cancer, including the new chemicals such as proautophagic drugs and kinases inhibitors, and differentiating agents. In this field, there have been opening new perspectives as the discovery of possible specific targets such as the EGFRvIII, a truncated form of the EGF receptor. Antibodies against these targets can be used as proapoptotic agents and as possible carriers for chemicals, drugs, radioisotopes, and toxins. In this paper, we review the possible mechanism of action of these therapies, with particular attention to the combined use of toxic substances (for example, immunotoxins) and antiproliferative/differentiating compounds (i.e., ATRA, PPARγ agonists). All these aspects will be discussed in the view of progress clinical trials and of possible new approaches for directed drug formulations.